The most utilized ultrasound enhancing agent is approved for use in pediatric patients
Data on file, Lantheus.
We remain grateful for the work all health care workers and government officials are doing to keep our communities healthy and safe. We send our thoughts and prayers to those affected by COVID-19 and will continue to do our part to keep our teams and our communities safe and to support our customers and the patients they serve.
62%
COVID-19: Clinical Experience with DEFINITY® from
the Front Line in NYC
A question and answer session with Dr. Martin Goldman, Dr. Lori Croft, and Samantha Buckley, RDCS of Mount Sinai Hospital in New York City. They share their experience treating patients and provide insight into the use of DEFINITY® during the COVID-19 pandemic.
American Society of Echocardiography Coronavirus (COVID-19) Resources
American College of Cardiology COVID-19 Hub
References:
Sperling D, Lai AC, Bienstock SW, et al. Echocardiography in the time of Covid-19: ultrasound enhancing agents save time and augment diagnostic information. Int J Cardiol. 2022;346:100-102. doi:10.1016/j.ijcard.2021.11.040
DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.